Literature DB >> 32462811

Epidemiology and cost of Lyme disease-related hospitalizations among patients with employer-sponsored health insurance-United States, 2005-2014.

Amy M Schwartz1, Manjunath B Shankar2, Kiersten J Kugeler1, Ryan J Max1, Alison F Hinckley1, Martin I Meltzer2, Christina A Nelson1.   

Abstract

An estimated 300,000 cases of Lyme disease occur in the United States annually. Disseminated Lyme disease may result in carditis, arthritis, facial palsy or meningitis, sometimes requiring hospitalization. We describe the epidemiology and cost of Lyme disease-related hospitalizations. We analysed 2005-2014 data from the Truven Health Analytics MarketScan Commercial Claims and Encounters Databases to identify inpatient records associated with Lyme disease based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. We estimated the annual number and median cost of Lyme disease-related hospitalizations in the United States in persons under 65 years of age. Costs were adjusted to reflect 2016 dollars. Of 20,983,165 admission records contained in the inpatient databases during the study period, 2,823 (0.01%) met inclusion criteria for Lyme disease-related hospitalizations. Over half of the identified records contained an ICD-9-CM code for meningitis (n = 614), carditis (n = 429), facial palsy (n = 400) or arthritis (n = 377). Nearly 60% of hospitalized patients were male. The median cost per Lyme disease-related hospitalization was $11,688 (range: $140-$323,613). The manifestation with the highest median cost per stay was carditis ($17,461), followed by meningitis ($15,177), arthritis ($13,012) and facial palsy ($10,491). Median cost was highest among the 15- to 19-year-old age group ($12,991). Admissions occurring in January had the highest median cost ($13,777) for all study years. Based on extrapolation to the U.S. population, we estimate that 2,196 Lyme disease-related hospitalizations in persons under 65 years of age occur annually with an estimated annual cost of $25,826,237. Lyme disease is usually treated in an outpatient setting; however, some patients with Lyme disease require hospitalization, underscoring the need for effective prevention methods to mitigate these serious cases. Information from this analysis can aid economic evaluations of interventions that prevent infection and advances in disease detection. Published 2020. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Lyme disease; claims analysis; cost of illness; tick borne diseases

Mesh:

Year:  2020        PMID: 32462811      PMCID: PMC7521202          DOI: 10.1111/zph.12699

Source DB:  PubMed          Journal:  Zoonoses Public Health        ISSN: 1863-1959            Impact factor:   2.954


  25 in total

Review 1.  The prevention of Lyme disease with vaccine.

Authors:  G A Poland; R M Jacobson
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

Review 2.  The Lyme disease vaccine--a public health perspective.

Authors:  Angela K Shen; Paul S Mead; Charles B Beard
Journal:  Clin Infect Dis       Date:  2011-02       Impact factor: 9.079

3.  The cost of Lyme borreliosis.

Authors:  Cees C van den Wijngaard; Agnetha Hofhuis; Albert Wong; Margriet G Harms; G Ardine de Wit; Anna K Lugnér; Anita W M Suijkerbuijk; Marie-Josée J Mangen; Wilfrid van Pelt
Journal:  Eur J Public Health       Date:  2017-06-01       Impact factor: 3.367

4.  Epidemiology and cost of hospital care for Lyme borreliosis in Germany: lessons from a health care utilization database analysis.

Authors:  B Lohr; I Müller; M Mai; D E Norris; O Schöffski; K-P Hunfeld
Journal:  Ticks Tick Borne Dis       Date:  2014-10-19       Impact factor: 3.744

5.  The cost effectiveness of vaccinating against Lyme disease.

Authors:  M I Meltzer; D T Dennis; K A Orloski
Journal:  Emerg Infect Dis       Date:  1999 May-Jun       Impact factor: 6.883

6.  Lyme disease--what is the cost for Scotland?

Authors:  A W Joss; M M Davidson; D O Ho-Yen; A Ludbrook
Journal:  Public Health       Date:  2003-07       Impact factor: 2.427

7.  Risk Factors for Clinician-Diagnosed Lyme Arthritis, Facial Palsy, Carditis, and Meningitis in Patients From High-Incidence States.

Authors:  Natalie A Kwit; Christina A Nelson; Ryan Max; Paul S Mead
Journal:  Open Forum Infect Dis       Date:  2017-11-18       Impact factor: 3.835

8.  Epidemiology of Lyme borreliosis through two surveillance systems: the national Sentinelles GP network and the national hospital discharge database, France, 2005 to 2016.

Authors:  A Septfons; T Goronflot; B Jaulhac; V Roussel; S De Martino; S Guerreiro; T Launay; L Fournier; H De Valk; J Figoni; T Blanchon; E Couturier
Journal:  Euro Surveill       Date:  2019-03

9.  Characteristics and patient pathways of Lyme disease patients: a retrospective analysis of hospital episode data in England and Wales (1998-2015).

Authors:  John S P Tulloch; Valerie Decraene; Rob M Christley; Alan D Radford; Jenny C Warner; Roberto Vivancos
Journal:  BMC Public Health       Date:  2019-08-15       Impact factor: 3.295

10.  Lyme Borreliosis in Finland, 1995-2014.

Authors:  Eeva Sajanti; Mikko Virtanen; Otto Helve; Markku Kuusi; Outi Lyytikäinen; Jukka Hytönen; Jussi Sane
Journal:  Emerg Infect Dis       Date:  2017-08       Impact factor: 6.883

View more
  4 in total

1.  Human and Veterinary Vaccines for Lyme Disease.

Authors:  Nathaniel S O'Bier; Amanda L Hatke; Andrew C Camire; Richard T Marconi
Journal:  Curr Issues Mol Biol       Date:  2020-12-08       Impact factor: 2.081

2.  What Are the Costs of Diagnostics and Treatment of Lyme Borreliosis in Poland?

Authors:  Anna Maria Rogalska; Olga Pawełczyk; Krzysztof Solarz; Tomasz Holecki
Journal:  Front Public Health       Date:  2021-01-18

3.  Patient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005-2017.

Authors:  Alison M Binder; Paige A Armstrong
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.996

Review 4.  Gene-Specific Sex Effects on Susceptibility to Infectious Diseases.

Authors:  Marie Lipoldová; Peter Demant
Journal:  Front Immunol       Date:  2021-10-14       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.